Assessing the Impact of Psoriatic Arthritis on Patient Function and Quality of Life: Lessons Learned from Other Rheumatologic Conditions

Seminars in Arthritis and Rheumatism

Volumn 38, Issue 4, 2009, Pages 320-335

  Mease, Philip J ^a  

^a Seattle Rhumatology Associates   (United States)

Author keywords

assessment; function; psoriatic arthritis; quality of life

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

ANKYLOSING SPONDYLITIS; ARTHRITIS IMPACT MEASUREMENT SCALES; ARTICLE; FUNCTIONAL ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERNATIONAL CLASSIFICATION OF FUNCTIONING, DISABILITY AND HEALTH; MEDLINE; OUTCOME ASSESSMENT; PHYSICAL DISABILITY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITATIVE VALIDITY; QUALITY OF LIFE; RELIABILITY; RHEUMATOID ARTHRITIS; SHORT FORM 36; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; ARTHRITIS, PSORIATIC; HUMANS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS;

EID: 58549100094     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2008.01.003     Document Type: Article

References (172)

1. Husted J.A., Gladman D.D., Farewell V.T., and Cook R.J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 45 (2001) 151-158
2. Zachariae H., Zachariae R., Blomqvist K., Davidsson S., Molin L., Mork C., et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82 (2002) 108-113
3. Mease P.J., and Menter M.A. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 54 (2006) 685-704
4. Adams P.F., Hendershot G.E., and Marano M.A. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 (1999) 1-203
5. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 3 (2004) 121-128
6. Gelfand J.M., Gladman D.D., Mease P.J., Smith N., Margolis D.J., Nijsten T., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53 (2005) 573
7. Dubertret L., Mrowietz U., Ranki A., van de Kerkhof P.C., Chimenti S., Lotti T., et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155 (2006) 729-736
8. Zink A., Listing J., Klindworth C., and Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 60 (2001) 199-206
9. Gladman D.D., Antoni C., Mease P., Clegg D.O., and Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 suppl 2 (2005) ii14-ii17
10. Leonard D.G., O'Duffy J.D., and Rogers R.S. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 53 (1978) 511-518
11. Mease P., and Goffe B.S. Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 52 (2005) 1-19
12. Sokoll K.B., and Helliwell P.S. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 28 (2001) 1842-1846
13. Husted J.A., Gladman D.D., Long J.A., and Farewell V.T. A modified version of the Health Assessment Questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 13 (1995) 439-443
14. de Korte J., Sprangers M.A., Mombers F.M., and Bos J.D. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 9 (2004) 140-147
15. Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., and Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137 (2001) 280-284
16. Rapp S.R., Feldman S.R., Exum M.L., Fleischer Jr. A.B., and Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
17. McKenna S.P., Cook S.A., Whalley D., Doward L.C., Richards H.L., Griffiths C.E., et al. Development of the PSORIQOL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol 149 (2003) 323-331
18. Devrimci-Ozguven H., Kundakci T.N., Kumbasar H., and Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 14 (2000) 267-271
19. Gupta M.A., and Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139 (1998) 846-850
20. Mau W., Listing J., Huscher D., Zeidler H., and Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 32 (2005) 721-728
21. Wiles N.J., Scott D.G., Barrett E.M., Merry P., Arie E., Gaffney K., et al. Benchmarking: the five year outcome of rheumatoid arthritis assessed using a pain score, the Health Assessment Questionnaire, and the Short Form-36 (SF-36) in a community and a clinic based sample. Ann Rheum Dis 60 (2001) 956-961
22. Young A., Dixey J., Cox N., Davies P., Devlin J., Emery P., et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives?. Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 39 (2000) 603-611
23. Ariza-Ariza R., Hernandez-Cruz B., and Navarro-Sarabia F. Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 49 (2003) 483-487
24. Ward M.M. Predictors of the progression of functional disability in patients with ankylosing spondylitis. J Rheumatol 29 (2002) 1420-1425
25. Bostan E.E., Borman P., Bodur H., and Barca N. Functional disability and quality of life in patients with ankylosing spondylitis. Rheumatol Int 23 (2003) 121-126
26. MacKinnon J.R., Avison W.R., and McCain G.A. Pain and functional limitations in individuals with rheumatoid arthritis. Int J Rehabil Res 17 (1994) 49-59
27. Eurenius E., and Stenstrom C.H. Physical activity, physical fitness, and general health perception among individuals with rheumatoid arthritis. Arthritis Rheum 53 (2005) 48-55
28. Hootman J.M., Macera C.A., Ham S.A., Helmick C.G., and Sniezek J.E. Physical activity levels among the general US adult population and in adults with and without arthritis. Arthritis Rheum 49 (2003) 129-135
29. Katz P.P. The stresses of rheumatoid arthritis: appraisals of perceived impact and coping efficacy. Arthritis Care Res 11 (1998) 9-22
30. Dagfinrud H., Kjeken I., Mowinckel P., Hagen K.B., and Kvien T.K. Impact of functional impairment in ankylosing spondylitis: impairment, activity limitation, and participation restrictions. J Rheumatol 32 (2005) 516-523
31. Zink A., Braun J., Listing J., and Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27 (2000) 613-622
32. Belza B.L. Comparison of self-reported fatigue in rheumatoid arthritis and controls. J Rheumatol 22 (1995) 639-643
33. Dagfinrud H., Vollestad N.K., Loge J.H., Kvien T.K., and Mengshoel A.M. Fatigue in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 53 (2005) 5-11
34. Dernis-Labous E., Messow M., and Dougados M. Assessment of fatigue in the management of patients with ankylosing spondylitis. Rheumatology (Oxford) 42 (2003) 1523-1528
35. Bazzichi L., Maser J., Piccinni A., Rucci P., Del Debbio A., Vivarelli L., et al. Quality of life in rheumatoid arthritis: impact of disability and lifetime depressive spectrum symptomatology. Clin Exp Rheumatol 23 (2005) 783-788
36. Kosinski M., Kujawski S.C., Martin R., Wanke L.A., Buatti M.C., Ware Jr. J.E., et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 8 (2002) 231-240
37. West E., and Jonsson S.W. Health-related quality of life in rheumatoid arthritis in Northern Sweden: a comparison between patients with early RA, patients with medium-term disease and controls, using SF-36. Clin Rheumatol 24 (2005) 117-122
38. Sivas F., Ercin O., Tanyolac O., Barca N., Aydog S., and Ozoran K. The Nottingham Health Profile in rheumatoid arthritis: correlation with other health status measurements and clinical variables. Rheumatol Int 24 (2004) 203-206
39. Borman P., Toy G.G., Babaoglu S., Bodur H., Ciliz D., and Alli N. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol 26 (2007) 330-334
40. Davis J.C., van der Heijde D., Dougados M., and Woolley J.M. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 53 (2005) 494-501
41. Ward M.M. Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12 (1999) 247-255
42. Ozgul A., Peker F., Taskaynatan M.A., Tan A.K., Dincer K., and Kalyon T.A. Effect of ankylosing spondylitis on health-related quality of life and different aspects of social life in young patients. Clin Rheumatol 25 (2005) 168-174
43. van Tubergen A., Coenen J., Landewe R., Spoorenberg A., Chorus A., Boonen A., et al. Assessment of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum 47 (2002) 8-16
44. Chorus A.M., Miedema H.S., Wevers C.J., and van Der Linden S. Labour force participation among patients with rheumatoid arthritis. Ann Rheum Dis 59 (2000) 549-554
45. Kwoh C., Anderson L.G., Greene J.M., Johnson D.A., O'Dell J.R., Robbins M.L., et al. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46 (2002) 328-346
46. van der Heijde D., Calin A., Dougados M., Khan M.A., van der Linden S., and Bellamy N. Selection of instruments in the core set for DC-ART. SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group Assessments in Ankylosing Spondylitis. J Rheumatol 26 (1999) 951-954
47. Gladman D.D., Mease P.J., Krueger G., van der Heidje D.M., Antoni C., Helliwell P.S., et al. Outcome measures in psoriatic arthritis. J Rheumatol 32 (2005) 2262-2269
48. Gladman D.D., Strand V., Mease P.J., Antoni C., Nash P., and Kavanaugh A. OMERACT 7 psoriatic arthritis workshop: synopsis. Ann Rheum Dis 64 Suppl 2 (2005) ii115-ii116
49. Gladman D.D., Mease P.J., Healy P., Helliwell P.S., Fitzgerald O., Cauli A., et al. Outcome measures in psoriatic arthritis. J Rheumatol 34 (2007) 1159-1166
50. Gladman D.D., Mease P.J., Strand V., Healy P., Helliwell P.S., Fitzgerald O., et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 34 (2007) 1167-1170
51. Stucki G. International Classification of Functioning. Disability, and Health (ICF): a promising framework and classification for rehabilitation medicine Am J Phys Med Rehabil 84 (2005) 733-740
52. Stucki G., and Ewert T. How to assess the impact of arthritis on the individual patient: the WHO ICF. Ann Rheum Dis 64 (2005) 664-668
53. Stoll T., Brach M., Huber E.O., Scheuringer M., Schwarzkopf S.R., Konstanjsek N., et al. ICF Core Set for patients with musculoskeletal conditions in the acute hospital. Disabil Rehabil 27 (2005) 381-387
54. Scheuringer M., Stucki G., Huber E.O., Brach M., Schwarzkopf S.R., Kostanjsek N., et al. ICF Core Set for patients with musculoskeletal conditions in early post-acute rehabilitation facilities. Disabil Rehabil 27 (2005) 405-410
55. Stucki G., and Cieza A. The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning. Ann Rheum Dis 63 (2004) ii40-ii45
56. Berzon R., Hays R.D., and Shumaker S.A. International use, application and performance of health-related quality of life instruments. Qual Life Res 2 (1993) 367-368
57. Beaton D.E., Boers M., and Wells G.A. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol 14 (2002) 109-114
58. Boers M., Brooks P., Strand C.V., and Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 25 (1998) 198-199
59. Boers M., Brooks P., Simon L.S., Strand V., and Tugwell P. OMERACT: an international initiative to improve outcome measurement in rheumatology. Clin Exp Rheumatol 23 (2005) S10-S13
60. Cella D., and Nowinski C.J. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil 83 (2002) S10-S17
61. Kosinski M., Keller S.D., Hatoum H.T., Kong S.X., and Ware Jr. J.E. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med Care 37 (1999) MS10-MS22
62. Ruta D.A., Hurst N.P., Kind P., Hunter M., and Stubbings A. Measuring health status in British patients with rheumatoid arthritis: reliability, validity and responsiveness of the short form 36-item health survey (SF-36). Br J Rheumatol 37 (1998) 425-436
63. Wells G., Boers M., Shea B., Tugwell P., Westhovens R., Saurez-Almazor M., et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology International League of Associations for Rheumatology. J Rheumatol 26 (1999) 217-221
64. Salaffi F., Stancati A., and Carotti M. Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin Rheumatol 21 (2002) 478-487
65. Birrell F.N., Hassell A.B., Jones P.W., and Dawes P.T. How does the short form 36 health questionnaire (SF-36) in rheumatoid arthritis (RA) relate to RA outcome measures and SF-36 population values?. A cross-sectional study. Clin Rheumatol 19 (2000) 195-199
66. Hagen K.B., Smedstad L.M., Uhlig T., and Kvien T.K. The responsiveness of health status measures in patients with rheumatoid arthritis: comparison of disease-specific and generic instruments. J Rheumatol 26 (1999) 1474-1480
67. Gandhi S.K., Salmon J.W., Zhao S.Z., Lambert B.L., Gore P.R., and Conrad K. Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. Clin Ther 23 (2001) 1080-1098
68. Haywood K.L., Garratt A.M., Dziedzic K., and Dawes P.T. Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 41 (2002) 1380-1387
69. Fries J.F., Spitz P., Kraines R.G., and Holman H.R. Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980) 137-145
70. Bruce B., and Fries J.F. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1 (2003) 20
71. Bruce B., and Fries J.F. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30 (2003) 167-178
72. Hunt S.M., McKenna S.P., McEwen J., Backett E.M., Williams J., and Papp E. A quantitative approach to perceived health status: a validation study. J Epidemiol Community Health 34 (1980) 281-286
73. Fitzpatrick R., Ziebland S., Jenkinson C., and Mowat A. A comparison of the sensitivity to change of several health status instruments in rheumatoid arthritis. J Rheumatol 20 (1993) 429-436
74. Fitzpatrick R., Ziebland S., Jenkinson C., and Mowat A. A generic health status instrument in the assessment of rheumatoid arthritis. Br J Rheumatol 31 (1992) 87-90
75. McKenna S.P., Doward L.C., Whalley D., Tennant A., Emery P., and Veale D.J. Development of the PsAQOL: a quality of life instrument specific to psoriatic arthritis. Ann Rheum Dis 63 (2004) 162-169
76. Hurst N.P., Jobanputra P., Hunter M., Lambert M., Lochhead A., and Brown H. Validity of Euroqol-a generic health status instrument-in patients with rheumatoid arthritis. Economic and Health Outcomes Research Group. Br J Rheumatol 33 (1994) 655-662
77. Hurst N.P., Kind P., Ruta D., Hunter M., and Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36 (1997) 551-559
78. Marra C.A., Woolcott J.C., Kopec J.A., Shojania K., Offer R., Brazier J.E., et al. A comparison of generic, indirect utility measures (the HUI2. HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQOL and the HAQ) in rheumatoid arthritis Soc Sci Med 60 (2005) 1571-1582
79. Wolfe F., and Hawley D.J. Measurement of the quality of life in rheumatic disorders using the EuroQol. Br J Rheumatol 36 (1997) 786-793
80. van Tubergen A., Landewe R., Heuft-Dorenbosch L., Spoorenberg A., van der Heijde D., van der Tempel H., et al. Assessment of disability with the World Health Organisation Disability Assessment Schedule II in patients with ankylosing spondylitis. Ann Rheum Dis 62 (2003) 140-145
81. Taylor W.J., Myers J., Simpson R.T., McPherson K.M., and Weatherall M. Quality of life of people with rheumatoid arthritis as measured by the World Health Organization Quality of Life Instrument, short form (WHOQOL-BREF): score distributions and psychometric properties. Arthritis Rheum 51 (2004) 350-357
82. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
83. Krupp L.B., LaRocca N.G., Muir-Nash J., and Steinberg A.D. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46 (1989) 1121-1123
84. Unaeze J., Nijsten T., Murphy A., Ravichandran C., and Stern R.S. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 126 (2006) 1480-1489
85. Smets E.M., Garssen B., Bonke B., and De Haes J.C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 39 (1995) 315-325
86. Beck A.T., Ward C.H., Mendelson M., Mock J., and Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 4 (1961) 561-571
87. Chandarana P.C., Eals M., Steingart A.B., Bellamy N., and Allen S. The detection of psychiatric morbidity and associated factors in patients with rheumatoid arthritis. Can J Psychiatry 32 (1987) 356-361
88. Lerner D., Amick III B.C., Rogers W.H., Malspeis S., Bungay K., and Cynn D. The Work Limitations Questionnaire. Med Care 39 (2001) 72-85
89. Walker N., Michaud K., and Wolfe F. Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. J Rheumatol 32 (2005) 1006-1012
90. Hewlett S., Smith A.P., and Kirwan J.R. Values for function in rheumatoid arthritis: patients, professionals, and public. Ann Rheum Dis 60 (2001) 928-933
91. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 43 (2000) 2751-2761
92. Wells G.A., Tugwell P., Kraag G.R., Baker P.R., Groh J., and Redelmeier D.A. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 20 (1993) 557-560
93. Redelmeier D.A., and Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 153 (1993) 1337-1342
94. Mease P.J., Ganguly R., Wanke L., Yu E., and Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: Applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Annual Scientific Meeting of the American College of Rheumatology (2004) 2004 October 16-21; San Antonio, TX
95. Singh A., Mease P., Yu H., Chiou C.F., and Tsuji W. Health assessment questionnaire has similar psychometric properties in psoriatic arthritis and rheumatoid arthritis. Annual Scientific Meeting of the American College of Rheumatology (2005) 2005 November 12-17; San Diego, CA
96. Pincus T., Swearingen C., and Wolfe F. Toward a multidimensional Health Assessment Questionnaire (MDHAQ): assessment of advanced activities of daily living and psychological status in the patient-friendly health assessment questionnaire format. Arthritis Rheum 42 (1999) 2220-2230
97. Pincus T., Sokka T., and Kautiainen H. Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol 32 (2005) 1432-1439
98. Meenan R.F., Gertman P.M., and Mason J.H. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis Rheum 23 (1980) 146-152
99. Meenan R.F., Mason J.H., Anderson J.J., Guccione A.A., and Kazis L.E. AIMS2. The content and properties of a revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire. Arthritis Rheum 35 (1992) 1-10
100. Haavardsholm E.A., Kvien T.K., Uhlig T., Smedstad L.M., and Guillemin F. A comparison of agreement and sensitivity to change between AIMS2 and a short form of AIMS2 (AIMS2-SF) in more than 1,000 rheumatoid arthritis patients. J Rheumatol 27 (2000) 2810-2816
101. Husted J., Gladman D.D., Long J.A., and Farewell V.T. Relationship of the Arthritis Impact Measurement Scales to changes in articular status and functional performance in patients with psoriatic arthritis. J Rheumatol 23 (1996) 1932-1937
102. Husted J., Gladman D.D., Farewell V.T., and Long J.A. Validation of the revised and expanded version of the Arthritis Impact Measurement Scales for patients with psoriatic Arthritis. J Rheumatol 23 (1996) 1015-1019
103. Salaffi F., Bazzichi L., Stancati A., Neri R., Cazzato M., Consensi A., et al. Development of a functional disability measurement tool to assess early arthritis: the Recent-Onset Arthritis Disability (ROAD) questionnaire. Clin Exp Rheumatol 23 (2005) 628-636
104. Salaffi F., Stancati A., Neri R., Grassi W., and Bombardieri S. Measuring functional disability in early rheumatoid arthritis: the validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index. Clin Exp Rheumatol 23 (2005) S31-S42
105. Birrell F.N., Hassell A.B., Jones P.W., and Dawes P.T. Why not use OSRA?. A comparison of Overall Status in Rheumatoid Arthritis (RA) with ACR core set and other indices of disease activity in RA. J Rheumatol 25 (1998) 1709-1715
106. Symmons D.P., Hassell A.B., Gunatillaka K.A., Jones P.J., Schollum J., and Dawes P.T. Development and preliminary assessment of a simple measure of overall status in rheumatoid arthritis (OSRA) for routine clinical use. QJM 88 (1995) 429-437
107. Wolfe F., Michaud K., and Pincus T. Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. J Rheumatol 32 (2005) 1261-1266
108. Katz P.P., Pasch L.A., and Wong B. Development of an instrument to measure disability in parenting activity among women with rheumatoid arthritis. Arthritis Rheum 48 (2003) 935-943
109. de Jong Z., van der Heijde D., McKenna S.P., and Whalley D. The reliability and construct validity of the RAQOL: a rheumatoid arthritis-specific quality of life instrument. Br J Rheumatol 36 (1997) 878-883
110. Tijhuis G.J., de Jong Z., Zwinderman A.H., Zuijderduin W.M., Jansen L.M., Hazes J.M., et al. The validity of the Rheumatoid Arthritis Quality of Life (RAQOL) questionnaire. Rheumatology (Oxford) 40 (2001) 1112-1119
111. Greenwood M.C., Hakim A.J., and Doyle D.V. A simple extension to the Rheumatoid Arthritis Quality of Life Questionnaire (RAQol) to explore individual patient concerns and monitor group outcome in clinical practice. Rheumatology (Oxford) 45 (2006) 61-65
112. Wolfe F., Michaud K., and Pincus T. A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 32 (2005) 2410-2415
113. Weisman M.H., Paulus H.E., Russak S.M., Lubeck D.P., Chiou C.F., Sengupta N., et al. Development of a new instrument for rheumatoid arthritis: the Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA). Arthritis Rheum 49 (2003) 78-84
114. Russak S.M., Sherbourne C.D., Lubeck D.P., Paulus H.D., Chiou C.F., Sengupta N., et al. Validation of a rheumatoid arthritis health-related quality of life instrument, the CSHQ-RA. Arthritis Rheum 49 (2003) 798-803
115. Katz P.P. The impact of rheumatoid arthritis on life activities. Arthritis Care Res 8 (1995) 272-278
116. Katz P.P., and Alfieri W.S. Satisfaction with abilities and well-being: development and validation of a questionnaire for use among persons with rheumatoid arthritis. Arthritis Care Res 10 (1997) 89-98
117. Katz P.P., Morris A., and Yelin E.H. Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 763-769
118. Daltroy L.H., Larson M.G., Roberts N.W., and Liang M.H. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 17 (1990) 946-950
119. Sigl T., Cieza A., van der Heijde D., and Stucki G. ICF based comparison of disease specific instruments measuring physical functional ability in ankylosing spondylitis. Ann Rheum Dis 64 (2005) 1576-1581
120. Blackmore M.G., Gladman D.D., Husted J., Long J.A., and Farewell V.T. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 22 (1995) 886-893
121. Guillemin F., Challier B., Urlacher F., Vancon G., and Pourel J. Quality of life in ankylosing spondylitis: validation of the ankylosing spondylitis Arthritis Impact Measurement Scales 2, a modified Arthritis Impact Measurement Scales Questionnaire. Arthritis Care Res 12 (1999) 157-162
122. Dougados M., Gueguen A., Nakache J.P., Nguyen M., Mery C., and Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 15 (1988) 302-307
123. Heikkila S. The Dougados Functional Index with the 5-point Likert scale is sensitive to change due to intensive physiotherapy and exercise in spondyloarthropathy. Clin Exp Rheumatol 20 (2002) 689-692
124. Falkenbach A., Franke A., Van Tubergen A., and Van Der Linden S. Assessment of functional ability in younger and older patients with ankylosing spondylitis: performance of the bath ankylosing spondylitis functional index. Am J Phys Med Rehabil 81 (2002) 416-420
125. Calin A., Garrett S., Whitelock H., Kennedy L.G., O'Hea J., Mallorie P., et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21 (1994) 2281-2285
126. Calin A., Nakache J.P., Gueguen A., Zeidler H., Mielants H., and Dougados M. Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity. J Rheumatol 26 (1999) 975-979
127. Ruof J., Sangha O., and Stucki G. Comparative responsiveness of 3 functional indices in ankylosing spondylitis. J Rheumatol 26 (1999) 1959-1963
128. Spoorenberg A., van der Heijde D., de Klerk E., Dougados M., de Vlam K., Mielants H., et al. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol 26 (1999) 961-965
129. Eyres S., Tennant A., Kay L., Waxman R., and Helliwell P.S. Measuring disability in ankylosing spondylitis: comparison of bath ankylosing spondylitis functional index with revised Leeds Disability Questionnaire. J Rheumatol 29 (2002) 979-986
130. Taylor A.L., Balakrishnan C., and Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 41 (1998) 1119-1125
131. Pavy S., Brophy S., and Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 32 (2005) 80-85
132. Singh A., Wajdula J., and Fatenejad S. Clinically meaningful changes in functional status in patients with ankylosing spondylitis receiving etanercept (Enbrel®) or placebo. ACR/ARHP Annual Scientific Meeting (2005) 2005 November 12-17; San Diego
133. Doward L.C., Spoorenberg A., Cook S.A., Whalley D., Helliwell P.S., Kay L.J., et al. Development of the ASQOL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 62 (2003) 20-26
134. Haywood K.L., Garratt A.M., Jordan K., Dziedzic K., and Dawes P.T. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 41 (2002) 1295-1302
135. Haywood K.L., Garratt A.M., Dziedzic K., and Dawes P.T. Patient centered assessment of ankylosing spondylitis-specific health related quality of life: evaluation of the Patient Generated Index. J Rheumatol 30 (2003) 764-773
136. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19 (1994) 210-216
137. Reich K., Nestle F.O., Papp K., Ortonne J.P., Wu Y., Bala M., et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol 154 (2006) 1161-1168
138. Menter A., Gordon K., Carey W., Hamilton T., Glazer S., Caro I., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
139. Krueger G.G., Langley R.G., Finlay A.Y., Griffiths C.E., Woolley J.M., Lalla D., et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol 153 (2005) 1192-1199
140. Feldman S.R., Gordon K.B., Bala M., Evans R., Li S., Dooley L.T., et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br J Dermatol 152 (2005) 954-960
141. Menter A., Kosinski M., Bresnahan B.W., Papp K.A., and Ware Jr. J.E. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 3 (2004) 27-38
142. Feldman S.R., Menter A., and Koo J.Y. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 150 (2004) 317-326
143. Shikiar R., Bresnahan B.W., Stone S.P., Thompson C., Koo J., and Revicki D.A. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes 1 (2003) 53
144. Morgan M., McCreedy R., Simpson J., and Hay R.J. Dermatology quality of life scales-a measure of the impact of skin diseases. Br J Dermatol 136 (1997) 202-206
145. Ellis C.N., Mordin M.M., and Adler E.Y. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 4 (2003) 131-139
146. Finlay A.Y., Salek M.S., and Haney J. Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. Dermatology 206 (2003) 307-315
147. Koo J., and Menter A. The Koo-Menter instrument for identification of psoriasis patients requiring systemic therapy. Natl Psoriasis Found Psoriasis Forum 9 (2003) 6-9
148. Finlay A.Y., and Kelly S.E. Psoriasis-an index of disability. Clin Exp Dermatol 12 (1987) 8-11
149. Gupta M.A., and Gupta A.K. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol 75 (1995) 240-243
150. Kirby B., Fortune D.G., Bhushan M., Chalmers R.J., and Griffiths C.E. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 142 (2000) 728-732
151. Finlay A.Y., Khan G.K., Luscombe D.K., and Salek M.S. Validation of sickness impact profile and psoriasis disability index in psoriasis. Br J Dermatol 123 (1990) 751-756
152. Fortune D.G., Main C.J., O'Sullivan T.M., and Griffiths C.E. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 137 (1997) 755-760
153. Kirby B., Richards H.L., Woo P., Hindle E., Main C.J., and Griffiths C.E. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 45 (2001) 72-76
154. Feletar M., Brockbank J.E., Schentag C.T., Lapp V., and Gladman D.D. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 63 (2004) 156-161
155. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50 (2004) 2264-2272
156. Kavanaugh A., Antoni C., Krueger G.G., Yan S., Bala M., Dooley L.T., et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 65 (2006) 471-477
157. Gladman D.D., Mease P.J., Cifaldi M.A., Perdok R.J., Sasso E., and Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis 66 (2007) 163-168
158. Frankel E.H., Strober B.E., Crowley J.J., Fivenson D.P., Woolley J.M., Yu E.B., et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. Cutis 79 (2007) 322-326
159. Husted J.A., Gladman D.D., Cook R.J., and Farewell V.T. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 25 (1998) 2146-2155
160. Kaltwasser J.P., Nash P., Gladman D., Rosen C.F., Behrens F., Jones P., et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 50 (2004) 1939-1950
161. Fraser A.D., van Kuijk A.W., Westhovens R., Karim Z., Wakefield R., Gerards A.H., et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64 (2005) 859-864
162. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
163. Mease P., Gottleib A., Woolley J.M., and Dunn M. Sustained improvements in patient-reported outcomes in psoriatic arthritis patients treated with etanercept [abstract P5]. J Am Acad Dermatol 52 suppl (2005) P2
164. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 52 (2005) 1227-1236
165. Mease P., Gladman D., Ritchlin C., Ruderman E., Steinfeld S., Choy E., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52 (2005) 3279-3289
166. Cieza A., and Stucki G. Content comparison of health-related quality of life (HRQOL) instruments based on the international classification of functioning, disability and health (ICF). Qual Life Res 14 (2005) 1225-1237
167. Hill C.L., Zhang Y., Sigurgeirsson B., Pukkala E., Mellemkjaer L., Airio A., et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357 (2001) 96-100
168. Ren X.S., Kazis L., and Meenan R.F. Short-form Arthritis Impact Measurement Scales 2: tests of reliability and validity among patients with osteoarthritis. Arthritis Care Res 12 (1999) 163-171
169. Taal E., Rasker J.J., and Riemsma R.P. Sensitivity to change of AIMS2 and AIMS2-SF components in comparison to M-HAQ and VAS-pain. Ann Rheum Dis 63 (2004) 1655-1658
170. Haywood K.L., Garratt A.M., Jordan K., Dziedzic K., and Dawes P.T. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 41 (2002) 1295-1302
171. Jones S.D., Steiner A., Garrett S.L., and Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35 (1996) 66-71
172. Nash P., Thaci D., Behrens F., Falk F., and Kaltwasser J.P. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212 (2006) 238-249